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Ronald F van Vollenhoven1*, György Nagy2,3 and Paul P Tak4,5,6Abstract
Despite considerable advances in the management of rheumatoid arthritis, results are still not satisfactory for all
patients. The treatment goal in rheumatoid arthritis is remission, and there currently are numerous conventional
and biological medications available to reach this aim. There are also different treatment strategies but with only
limited comparative evidence about their efficacies. More patients now achieve remission while on treatment, but it
remains elusive in the majority of patients. Treatment-free remission, the ultimate goal of therapy, is only achieved
in very few patients; even when this happens, it is most likely due to the natural course of the disease rather than
to any specific therapies. Modern treatment is based on the initiation of aggressive therapy as soon as the diagnosis
is established, and on modifying or intensifying therapy guided by frequent assessment of disease activity. In this
commentary we will discuss the current treatment paradigm as well as the possibility of an induction-maintenance
regimen with biological disease-modifying antirheumatic drugs in early rheumatoid arthritis.
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The goals of treatment of rheumatoid arthritis (RA) include
induction of disease remission and protection against
progressive joint destruction [1]. As early RA already
represents chronic synovial inflammation [2], which may
lead to erosive disease during the first months to years
after clinical onset of the disease [3], effective antirheumatic
treatment needs to be initiated as soon as the diagnosis has
been established. It is generally accepted that early control
of inflammation results in a better outcome in terms of
joint damage, functional status and quality of life. Currently,
patients with RA usually start with conventional disease-
modifying antirheumatic drugs (DMARDs) and switch to
biological treatment if there is persistent disease activity in
spite of optimal conventional treatment [1,4]. Whether
biologicals might prevent the initiation of RA in high-risk
individuals (for example, persons with anti-cyclic citrulli-
nated peptide positivity, arthralgia and genetic susceptibility)
is unclear; ongoing studies are attempting to address
this question (Tak, personal communication).* Correspondence: Ronald.van.vollenhoven@ki.se
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2014Following the advent of anti-TNF therapies, studies with
such agents clearly demonstrated that a combination of
anti-TNF with methotrexate (MTX) in early RA achieved
significantly better results, at least at the group level, than
MTX monotherapy [5-7]. A direct comparison between
conventional DMARD combinations with MTX plus anti-
TNF was needed, and such a comparison was made in both
the Swedish Farmacotherapy (Swefot) and the Treatment of
Early Aggressive Rheumatoid Arthritis (TEAR) clinical
trials. In the Swefot trial, a significant clinical advantage
for anti-TNF was demonstrated after the first [8], but not
after the second year - the latter finding being attributable
both to a slow incremental benefit of the conventional
agents and a lack of statistical power (type II error) [9].
The two-year results did confirm that the anti-TNF com-
bination was superior in preventing radiographic damage.
The TEAR trial confirmed neither the clinical nor the
radiographic benefit of anti-TNF over conventional com-
bination therapy, but featured a more complex design and
analysis that may have underestimated the differences be-
tween the treatment arms [10]. The NEO-RACo trial was
designed to study the long-term outcomes of the combin-
ation of MTX, sulfasalazine, hydroxychloroquine and
prednisolone treatment with and without additional inflix-
imab therapy [11]. This study showed that the long-termd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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prednisolone was not further improved by adding inflixi-
mab during the first six months of treatment.
That disease control can be achieved with conventional
DMARDs in a significant proportion of patients, in par-
ticular when these drugs are used in combination, is
also supported by other studies. The Finnish Rheumatoid
Arthritis Combination Therapy (FIN-RACo) trial, for in-
stance, demonstrated that combination therapy is superior
to monotherapy [12]. The Optimized Treatment Algorithm
for Patients with Early Rheumatoid Arthritis (OPERA)
study revealed that conventional treatment using MTX and
frequent intra-articular glucocorticoid injections achieved
very good results in early RA but that the addition of anti-
TNF to this regimen yielded even better results, achieving
remission in a remarkably high proportion of patients [13].
In the Rotterdam Early Arthritis Cohort (tREACH), re-
searchers in the Netherlands studied the efficacy of triple
DMARD therapy (MTX, sulfasalazine and hydroxychloro-
quine) with the use of glucocorticoids in early RA [14].
This study further confirmed that triple DMARD in-
duction therapy is better than MTX monotherapy, and
suggested that oral and intramuscular glucocorticoids
were equally effective as bridging therapy. Another study
showed that both triple therapy (sulfasalazine, hydroxy-
chloroquine and MTX) and combination therapy (etaner-
cept plus MTX) were effective in patients with RA who
had active disease despite MTX therapy [15].
Taken together, these data show that different approaches
can be used to induce disease remission in patients with
early RA for whom MTX monotherapy fails. More work
is clearly needed on the cost-effectiveness of conventional
DMARD regimens compared to biological treatment. Con-
sidering cost-effectiveness, it is particularly important how
biological therapy versus conventional combination treat-
ment alters the work loss outcomes. In a recently published
sub-analysis from the Swefot trial, working-age patients
were studied. A similar reduction in the number of days
with sick leave or disability pension was observed in both
those patients receiving conventional DMARD combina-
tions with MTX and those receiving anti-TNF [16].
An important development in the approach to early
RA has been the demonstration, in several randomized
trials, that frequent monitoring and a prespecified target
yield better results - although with a more frequent usage
of glucocorticoids and at higher costs - than the more com-
mon practice of three-monthly follow-up and adjusting
treatments based on general impressions [17,18]. ‘Treat-
to-target’ has become the accepted term for what is dem-
onstrably a more successful approach. Using this approach
and aiming for disease remission, a significant proportion
of patients with RA will need biological treatment at some
stage after optimal conventional DMARD treatment fails.
Currently, 40% to 50% of patients with moderate to severeRA in the USA use biologics. Many of these patients will
subsequently be using biological treatment for several
years.
An important research question is whether the treatment
paradigm could be changed in a cost-effective way by
reversing the order of medicines that are used to treat
RA. One such method would be to use an ‘induction-
maintenance’ type of approach: to start the most effective
agents, including biologics, very early in the course of the
disease in the hope of achieving excellent results but also
of being able to later withdraw these agents to minimize
exposure to risks and achieve better cost-effectiveness. To
what extent is such an approach supported by current
data? First, biological treatment is more effective when
initiated during the earliest stages of RA compared to
later stages, an effect that has been shown for different
mechanism of action, such as etanercept [19], tocilizumab
[20], abatacept [21] and rituximab [22]. Based on these
and other studies, it has been suggested that there is a
therapeutic window of opportunity [23]. It is tempting to
speculate that this clinical observation might be explained
by the differences between early RA and late-stage RA in
synovial tissue mass; progressive joint destruction, which
may be lead to the release of proinflammatory crystals;
and epigenetic changes in fibroblast-like synoviocytes,
which could result in autonomous disease progression.
The question is whether interfering with this process of
autonomous disease progression with biological treatment
during the earliest stage after the disease becomes clinically
manifest could result in a disease that is easier to control
over time with just conventional DMARDs. An early indi-
cation that this may be possible came from the small but
randomized trial by Quinn et al. [24], where 10 patients
were given MTX plus infliximab as first-line therapy for
RA. After one year the biologic was discontinued and the
excellent responses seen in most of the patients were
maintained for an additional year of follow-up. The
same initial treatment was used in the fourth arm of
the Behandelings Strategiën (BeSt). Here, 120 patients
received MTX plus infliximab for nine months and 87
achieved a good response; of those, 77 were able to main-
tain the response with MTX alone after the biologic
had been stopped, again suggesting the effectiveness of
induction-maintenance [25]. Very recently, these results
were confirmed using initial treatment with MTX plus
adalimumab in the Optimal Protocol for Methotrexate and
Adalimumab Combination Therapy in Early Rheumatoid
Arthritis (OPTIMA) study [26]. In this large randomized
trial, 44% of patients achieved the low-disease-activity target
at 24 to 26 weeks with the combination treatment (versus
24% with MTX plus placebo). These patients were then
re-randomized to either continuation of the combination
of both, or continuation with MTX plus placebo. After
an additional year, 91% of patients in the continued
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continuation group had maintained low disease activity,
demonstrating that for many patients the MTX mainten-
ance therapy was effective. A formal cost-effectiveness ana-
lysis based on this trial has not yet been performed, but it
seems reasonable to assume that induction-maintenance
with biologics may not only be an effective way of treating
the disease with rapid achievement of therapeutic targets in
higher proportions of patients, but also a cost-effective
way of using expensive agents for a limited period of time
to bring the disease to a stable low-activity state (or to
remission), which can then be sustained with simpler
means. If the health-economic feasibility can be formally
demonstrated, early start and stop of biologics may well
become the new paradigm for treating early RA.Conclusions
Disease remission can be achieved in a significant pro-
portion of patients with early RA by optimal use of con-
ventional DMARDs. Biological DMARDs are indicated
in patients with persistent disease activity, and are sub-
sequently used for chronic treatment. We discuss the pos-
sibility of a novel treatment paradigm where biological
DMARD treatment is used for a limited period of time
during the so-called therapeutic window of opportunity
to induce disease remission, followed by maintenance of re-
mission with conventional DMARDs. Future research needs
to address the question whether this may be a more cost-
effective approach than the current treatment paradigm.Abbreviations
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